drugset / Trial / NCT00494767

Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs

NCT00494767

Phase 1 Completed 27 enrolled GlaxoSmithKline
RandomizedParallel-groupTreatment

Summary

The drugs GSK189075 and GW869682 result in increased caloric losses. This study is investigating how if taken over 8 weeks that affects weight loss, food intake and the composition of the body. The body composition (fat,water, lean mass) is determined using a new investigational MR technology.

Timeline

Start
2006-09-29
Primary completion
2007-06-07
Completion
2007-06-07

Drugs

EvaluationDrugModalityDoseRoute
Subject GW869682 Unknown 1000 mg
Subject remogliflozin etabonate Small molecule 250 mg